These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 25234311

  • 1. Endothelial dysfunction and oxidative stress in polycystic kidney disease.
    Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW.
    Am J Physiol Renal Physiol; 2014 Dec 01; 307(11):F1198-206. PubMed ID: 25234311
    [Abstract] [Full Text] [Related]

  • 2. Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease.
    Raptis V, Georgianos PI, Sarafidis PA, Sioulis A, Makedou K, Makedou A, Grekas DM, Kapoulas S.
    Kidney Blood Press Res; 2013 Dec 01; 38(1):72-82. PubMed ID: 24577239
    [Abstract] [Full Text] [Related]

  • 3. Bioactive lipid mediators in polycystic kidney disease.
    Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Gitomer B, Christians U, Schrier RW.
    J Lipid Res; 2014 Jun 01; 55(6):1139-49. PubMed ID: 24343898
    [Abstract] [Full Text] [Related]

  • 4. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease.
    Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M.
    Clin J Am Soc Nephrol; 2011 Jan 01; 6(1):7-13. PubMed ID: 20829421
    [Abstract] [Full Text] [Related]

  • 5. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
    Coban M, Inci A.
    Int Urol Nephrol; 2018 Jul 01; 50(7):1293-1300. PubMed ID: 29654395
    [Abstract] [Full Text] [Related]

  • 6. Kidney Energetics and Cyst Burden in Autosomal Dominant Polycystic Kidney Disease: A Pilot Study.
    Bjornstad P, Richard G, Choi YJ, Nowak KL, Steele C, Chonchol MB, Nadeau KJ, Vigers T, Pyle L, Tommerdahl K, van Raalte DH, Hilkin A, Driscoll L, Birznieks C, Hopp K, Wang W, Edelstein C, Nelson RG, Gregory AV, Kline TL, Blondin D, Gitomer B.
    Am J Kidney Dis; 2024 Sep 01; 84(3):286-297.e1. PubMed ID: 38621633
    [Abstract] [Full Text] [Related]

  • 7. Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL, Wang W, Farmer-Bailey H, Gitomer B, Malaczewski M, Klawitter J, Jovanovich A, Chonchol M.
    Clin J Am Soc Nephrol; 2018 Oct 08; 13(10):1493-1501. PubMed ID: 30228110
    [Abstract] [Full Text] [Related]

  • 8. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
    Kim K, Trott JF, Gao G, Chapman A, Weiss RH.
    BMC Nephrol; 2019 Feb 25; 20(1):66. PubMed ID: 30803434
    [Abstract] [Full Text] [Related]

  • 9. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A, Lu Y, Kawano H, Horie S, Muto S.
    Clin Exp Nephrol; 2015 Dec 25; 19(6):1199-205. PubMed ID: 25715868
    [Abstract] [Full Text] [Related]

  • 10. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease.
    Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS.
    Am J Kidney Dis; 2008 Feb 25; 51(2):184-91. PubMed ID: 18215696
    [Abstract] [Full Text] [Related]

  • 11. Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.
    Heffernan KS, Kuvin JT, Sarnak MJ, Perrone RD, Miskulin DC, Rudym D, Chandra P, Karas RH, Menon V.
    Nephrol Dial Transplant; 2011 Aug 25; 26(8):2515-21. PubMed ID: 21292815
    [Abstract] [Full Text] [Related]

  • 12. Exercise capacity in polycystic kidney disease.
    Reinecke NL, Cunha TM, Heilberg IP, Higa EM, Nishiura JL, Neder JA, Almeida WS, Schor N.
    Am J Kidney Dis; 2014 Aug 25; 64(2):239-46. PubMed ID: 24787761
    [Abstract] [Full Text] [Related]

  • 13. Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function.
    Raptis V, Bakogiannis C, Loutradis C, Boutou AK, Sioulis A, Balaskas E, Zebekakis P, Sarafidis PA.
    Kidney Blood Press Res; 2018 Aug 25; 43(3):744-754. PubMed ID: 29794429
    [Abstract] [Full Text] [Related]

  • 14. Kidney volume and function in autosomal dominant polycystic kidney disease.
    Higashihara E, Nutahara K, Okegawa T, Shishido T, Tanbo M, Kobayasi K, Nitadori T.
    Clin Exp Nephrol; 2014 Feb 25; 18(1):157-65. PubMed ID: 23864346
    [Abstract] [Full Text] [Related]

  • 15. Left ventricular hypertrophy in a contemporary cohort of autosomal dominant polycystic kidney disease patients.
    Chen H, Watnick T, Hong SN, Daly B, Li Y, Seliger SL.
    BMC Nephrol; 2019 Oct 25; 20(1):386. PubMed ID: 31653199
    [Abstract] [Full Text] [Related]

  • 16. Association of OSR-1 With Vascular Dysfunction and Hypertension in Polycystic Kidney Disease.
    Kocyigit I, Taheri S, Eroglu E, Zararsiz G, Sener EF, Uzun I, Imamoglu H, Mehmetbeyoglu E, Unal A, Korkmaz K, Sipahioglu MH, Oymak O, Tokgoz B.
    Ther Apher Dial; 2020 Feb 25; 24(1):64-71. PubMed ID: 31020807
    [Abstract] [Full Text] [Related]

  • 17. Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function.
    Raptis V, Loutradis C, Boutou AK, Faitatzidou D, Sioulis A, Ferro CJ, Papagianni A, Sarafidis PA.
    Cardiorenal Med; 2020 Feb 25; 10(6):440-451. PubMed ID: 33202410
    [Abstract] [Full Text] [Related]

  • 18. Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function.
    Raptis V, Bakogiannis C, Loutradis C, Boutou AK, Lampropoulou I, Intzevidou E, Sioulis A, Balaskas E, Sarafidis PA.
    Am J Nephrol; 2018 Feb 25; 47(4):231-238. PubMed ID: 29597186
    [Abstract] [Full Text] [Related]

  • 19. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
    Uchiyama K, Mochizuki T, Shimada Y, Nishio S, Kataoka H, Mitobe M, Tsuchiya K, Hanaoka K, Ubara Y, Suwabe T, Sekine A, Nutahara K, Tsuruya K, Ishimura E, Nakatani S, Sofue T, Tanaka S, Narita I, Maruyama S, Horie S, Muto S.
    Clin Exp Nephrol; 2021 Sep 25; 25(9):970-980. PubMed ID: 33928479
    [Abstract] [Full Text] [Related]

  • 20. Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease.
    Chen D, Ma Y, Wang X, Yu S, Li L, Dai B, Mao Z, Sun L, Xu C, Rong S, Tang M, Zhao H, Liu H, Serra AL, Graf N, Liu S, Wüthrich RP, Mei C.
    PLoS One; 2014 Sep 25; 9(3):e92232. PubMed ID: 24651850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.